Physician profile
James E Wheeler
NPI 1275537094
$9,521.65
in general payments reported to CMS, 2019-2025
51 companies · $1,155 in 2025
The $1,155 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,956 · 2020: $1,427 · 2021: $1,471 · 2022: $1,089 · 2023: $1,207 · 2024: $1,217 · 2025: $1,155.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,579.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,578.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,314.57 | 2020-2025 | Vraylar, Ubrelvy, Qulipta |
| Amgen INC. | $1,049.61 | 2019-2025 | Repatha, Otezla, Otezla |
| Novo Nordisk INC | $846.29 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $664.69 | 2019-2022 | |
| Glaxosmithkline, LLC. | $625.23 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Astrazeneca Pharmaceuticals Lp | $588.87 | 2019-2025 | Airsupra, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $470.81 | 2019-2025 | Jardiance, Ofev, Tradjenta |
| Pfizer INC. | $444.75 | 2020-2025 | |
| Sunovion Pharmaceuticals INC. | $340.88 | 2019-2021 | |
| Lilly USA, LLC | $320.26 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amarin Pharma, INC. | $280.53 | 2019-2023 | |
| Esperion Therapeutics, INC. | $252.12 | 2021-2025 | Nexletol |
| Sanofi-Aventis U.S. LLC | $209.55 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $193.39 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Novartis Pharmaceuticals Corporation | $170.07 | 2019-2025 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Wheeler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.